Capstone Therapeutics (CAPS) Stock Price, News & Analysis

Company Overview

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.

Key Stats

• Today's Range: $0.18 to $0.19
• 50-Day Range: $0.19 to $0.32
• 52-Week Range: $0.18 to $2.07
• Volume: 206,147 shs
• Average Volume: 1.85 million shs
• Market Capitalization: $2.84 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Capstone Therapeutics Stock Analysis - MarketRank™

Capstone Therapeutics scored higher than 8% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Capstone Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Capstone Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Capstone Therapeutics is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Capstone Therapeutics is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Capstone Therapeutics has a P/B Ratio of 0.23. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.38% of the float of Capstone Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Capstone Therapeutics has a short interest ratio ("days to cover") of 3.27, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Capstone Therapeutics has recently increased by 1.42%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Capstone Therapeutics does not currently pay a dividend.

Dividend Growth

Capstone Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Capstone Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

39.29% of the stock of Capstone Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

2.55% of the stock of Capstone Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 11/18/2025
• Today: 8/21/2026
• Next Earnings (Estimated): 11/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Industrials
• Industry: Trading Companies & Distributors
• Sub-Industry: Trading Companies & Distributors
• Current Symbol: NASDAQ:CAPS
• Previous Symbol: OTCMKTS:CAPS
• CIK: 887151
• Web: www.capstonethx.com
• Phone: (708) 371-0660
• Fax: 602-286-5300
• Employees: 38
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($3.35)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$21.23 million
• Net Margins: -36.51%
• Pretax Margin: -24.64%
• Return on Equity: -144.43%
• Return on Assets: -40.48%

Debt

• Debt-to-Equity Ratio: 0.69
• Current Ratio: 0.99
• Quick Ratio: 0.39

Sales & Book Value

• Annual Sales: $48.11 million
• Price / Sales: 0.06
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.81 per share
• Price / Book: 0.23

Miscellaneous

• Outstanding Shares: 15,200,000
• Free Float: 9,230,000
• Market Cap: $2.84 million
• Optionable: N/A
• Beta: -1.52